Novo Nordisk A/S (NOVO-B.KO) said Thursday it is buying Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Indiana, U.S., for undisclosed sums.

The Danish pharmaceutical company said the acquisition will expand its portfolio of projects and intellectual property rights within diabetes and obesity, and provide a basis for expanding its research presence in the U.S..

Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases.

The parties have agreed not to disclose the financial details of the transactions which is expected to close in the third quarter of 2015.

-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

August 27, 2015 09:23 ET (13:23 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Novo Nordisk Charts.